CAS 851199-59-2

Linaclotide

Description:

Linaclotide is a synthetic peptide used primarily as a medication for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It functions as a guanylate cyclase-C agonist, which leads to increased levels of cyclic guanosine monophosphate (cGMP) in intestinal epithelial cells. This action promotes fluid secretion into the intestinal lumen and accelerates gastrointestinal transit, alleviating constipation symptoms. Linaclotide is characterized by its relatively low oral bioavailability due to its peptide nature, which limits its absorption in the gastrointestinal tract. The substance is typically administered in a capsule form and is known for its specific mechanism of action, which targets the intestinal lining rather than systemic pathways. Common side effects may include diarrhea, abdominal pain, and flatulence. Linaclotide's efficacy and safety profile have been established through clinical trials, making it a valuable option in the management of certain gastrointestinal disorders.

Linaclotide

CAS: 851199-59-2

Formula: C₅₉H₇₉N₁₅O₂₁S₆

Purity: 99%

Color and Shape: Solid

Molecular weight: 1526.7365

Ref: IN-DA00G3R9

Linaclotide

CAS: 851199-59-2

Linaclotide treats IBS-C & chronic constipation; it's a selective guanylate cyclase C agonist.

Formula: C₅₉H₇₉N₁₅O₂₁S₆

Purity: 97.93% - 98.71%

Color and Shape: Solid

Molecular weight: 1526.74

Ref: TM-T11852

Linaclotide

CAS: 851199-59-2

Formula: C₅₉H₇₉N₁₅O₂₁S₆

Molecular weight: 1526.73

Ref: 4Z-PL-121001

Linaclotide

CAS: 851199-59-2

Linaclotide

Purity: ≥95%

Molecular weight: 1526.74g/mol

Ref: 54-BUP05450

Linaelotide Acetate

CAS: 851199-59-2

Formula: C₅₉H₇₉N₁₅O₂₁S₆

Purity: 95%~99%

Color and Shape: White to Off-white Powder

Molecular weight: 1526.74

Ref: BP-BPPG045

Linaclotide-d4

CAS: 851199-59-2

Formula: C₅₉H₇₅N₁₅O₂₁S₆D₄

Molecular weight: 1530.78

Ref: 4Z-PL-121002

Linaclotide

CAS: 851199-59-2

Linaclotide is a drug that is used in the treatment of chronic idiopathic constipation. It is formulated with the inactive ingredients microcrystalline cellulose, croscarmellose sodium, calcium stearate, and magnesium stearate. The active ingredient is linaclotide hydrochloride. Linaclotide works by increasing intestinal motility and reducing transit time through the gastrointestinal tract. It has been shown to be effective in treating constipation in adults with chronic idiopathic constipation when taken for up to 12 weeks. Linaclotide also may be used in combination with other treatments for bowel diseases such as ulcerative colitis or Crohn's disease.
Linaclotide is metabolized primarily by cytochrome P450 3A4 (CYP3A4) and subsequently eliminated from the body primarily by renal excretion of unchanged drug or metabolites. The drug has a half-life of about 4 hours following oral administration and

Formula: C₅₉H₇₉N₁₅O₂₁S₆

Purity: Min. 98 Area-%

Color and Shape: White Powder

Molecular weight: 1,526.74 g/mol

Ref: 3D-FL138962

Linaclotide

CAS: 851199-59-2

Linaclotide is a peptide drug that has been shown to be effective in treating chronic constipation. It belongs to the class of pharmacological agents and is used as a treatment for bowel disease, specifically chronic idiopathic constipation. Linaclotide increases the frequency of bowel movements by acting on the ileum and colon. This drug has been shown to be safe for use in pregnant women and children, with no adverse effects observed at doses up to 100 mcg/kg/day. The most common side effect is diarrhea, which can be managed with dietary changes or other medications. Linaclotide has not been found to interact with other drugs, but patients should always consult their doctor before taking any new medication while on linaclotide.

Formula: C₅₉H₇₉N₁₅O₂₁S₆

Purity: Min. 95%

Molecular weight: 1,526.76 g/mol

Ref: 3D-LIN-3796-PI

Linaclotide

Controlled Product

CAS: 851199-59-2

Applications Linaclotide is a guanylate cyclase-C agonist currently being studied in Phase 3 trials for the treatment of irritable bowel syndrome with constipation.
References Chey, W.D., et al.: Am. J. Gastroenterol., 107, 1702 (2012); Rao, S., et al.: Am. J. Gastroentrol., 107, 1714 (2012); Brierley, S.M., et al.: Curr. Opinion. Pharmacol., 12, 632 (2012);

Formula: C₅₉H₇₉N₁₅O₂₁S₆

Color and Shape: Neat

Molecular weight: 1526.74

Ref: TR-L465880

Linaclotide-d4

Controlled Product

CAS: 851199-59-2

Applications Linaclotide-d4 is the labeled analogue of a guanylate cyclase-C agonist currently being studied in Phase 3 trials for the treatment of irritable bowel syndrome with constipation.
References Chey, W.D., et al.: Am. J. Gastroenterol., 107, 1702 (2012); Rao, S., et al.: Am. J. Gastroentrol., 107, 1714 (2012); Brierley, S.M., et al.: Curr. Opinion. Pharmacol., 12, 632 (2012);

Formula: C₅₉H₇₅D₄N₁₅O₂₁S₆

Color and Shape: Neat

Molecular weight: 1530.76

Ref: TR-L465882